Propeller Health and Boehringer Ingelheim announced a new commercial partnership. Under the partnership, COPD and asthma patients using Boehringer's Respimat inhaler will have the opportunity to ...
Madison, Wisconsin-based Propeller Health has secured two new FDA clearances for new sensors that are designed to work with two particular inhalers on the market: the Diskus inhaler from ...
Stiolto Respimat (tiotropium bromide/olodaterol) is an inhaled medication for the treatment of chronic obstructive pulmonary disease (COPD), bronchitis, and emphysema. However, it is not indicated for ...
March 7 (Reuters) - Boehringer Ingelheim will cap out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma at $35 per month starting June 1, the German drugmaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results